Company Filing History:
Years Active: 2002-2005
Title: **Inventor Elsebet Ostergard Nielsen: Pioneering Innovations in Cholinergic Ligands**
Introduction
Elsebet Ostergard Nielsen is a prominent inventor based in Ballerup, Denmark. She holds four patents that contribute significantly to the field of pharmacology, particularly in the development of nicotinic acetylcholine receptor ligands. Her work is characterized by innovative approaches to medicinal chemistry, enabling new therapeutic possibilities.
Latest Patents
Her latest patents include:
1. **Heteroaryl diazacycloalkanes, their preparation and use** - This invention discloses compounds of the formula, any of its enantiomers or any mixture thereof, isotopes thereof, or a pharmaceutically acceptable salt thereof. The compounds of the invention are particularly useful as nicotinic acetylcholine (ACh) receptor ligands.
2. **Certain heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors** - This patent describes compounds of formula (I) that could potentially enhance the understanding of cholinergic actions at nicotinic ACh receptors. The compounds include various substituents, expanding the therapeutic applications in neurological research.
Career Highlights
Elsebet has made a remarkable impact in the field through her tenure at Neurosearch A/S, where she focuses on the intersection of neuroscience and therapeutics. Her contributions to the pharmaceutical industry have not only resulted in multiple patents but have also gained recognition among her peers in the field.
Collaborations
Throughout her career, Elsebet has collaborated with several notable professionals, including Dan Peters and Gunnar M. Olsen. These partnerships have fostered a rich environment for innovation, driving advancements in treatments for neurological disorders.
Conclusion
Elsebet Ostergard Nielsen exemplifies the spirit of innovation through her contributions to the development of compounds that target nicotinic receptors. Her dedication to research and collaboration has positioned her as a key figure in pharmacological advancements, impacting the future of medical treatments.